CD19 and neoplasm: Results showed that CD19-CAR T cells engineered to secret anti-CD47 antibodies could enhance phagocytosis of macrophages compared with the conventional ones (Fig. 6D), suggesting that anti-CD47 scFv effectively slackens off the inhibitory impact of macrophage phagocytosis caused by CD47 overexpression in tumor cells.